Abstract: Provided is a method for preparing 7N tellurium, including the following steps: mixing 2N crude tellurium with concentrated sulfuric acid, and subjecting a resulting mixture to oxidation roasting to obtain a selenium dioxide vapor and a roasting residue; mixing the roasting residue with a strong base solution, and subjecting a resulting solution to electrolysis to obtain 4N electrolytic tellurium; subjecting the 4N electrolytic tellurium to vacuum distillation to obtain 5N tellurium; and melting the 5N tellurium to obtain a tellurium melt, immersing a crystallizer in the tellurium melt, and subjecting the tellurium melt to crystallization to obtain the 7N tellurium; wherein the method is performed for a total time of less than 14 days.

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.

Abstract: Provided is a method for preparing high-purity indium (In). The method for preparing the high-purity In includes: distilling refined In to obtain an In vapor-containing gas; and condensing the In vapor-containing gas to obtain the high-purity In; where the distilling is conducted at a temperature of 1,000° C. to 1,100° C. under a vacuum degree of 1.0×10?3 Pa to 5.0×10?2 Pa; and the condensing is conducted at a temperature of 700° C. to 900° C. under a vacuum degree of 1.0×10?3 Pa to 5.0×10?2 Pa. The In vapor-containing gas is obtained by controlling the temperature and vacuum degree of the distilling to evaporate In and impurities with a vapor pressure higher than the In. The temperature and vacuum degree of the condensing are adjusted to condense the In in the In vapor-containing gas.

Abstract: Disclosed is a method for removing impurity mercury from crude selenium. The method includes: mixing a vulcanizing agent with a crude selenium slag that is crushed to not more than 200 mesh uniformly, and performing briquetting to obtain a mixed material; adding the mixed material into a sealed furnace, and subjecting the mixed material to vulcanization by heating under an inert atmosphere to obtain a vulcanized selenium; subjecting the vulcanized selenium to primary vacuum distillation, such that selenium is converted into a gas phase and collected in a form of a volatile, and generated mercury sulfide and valuable elements are enriched in a resulting residue; and subjecting the selenium to secondary distillation to further remove mercury.

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: This invention presents an electrochemical metallurgical technique for extracting metals and sulfur from metal sulfides, offering an adjustable composition and mechanical properties during electrode preparation. The metal sulfide anode, submerged in an electrolyte with a cathode made of materials like titanium, copper, stainless steel, lead, zinc, aluminum or graphite, undergoes electrolysis. This process oxidizes sulfur in the metal sulfide to the anode and releases metal ions into the electrolyte, where they're reduced at the cathode. The method yields metal at the cathode and sulfur at the anode, with minimal environmental impact, low investment, and straightforward process.

Abstract: Provided is a recovery method for valuable metals in copper anode slime. By using the recovery method of the disclosure, selenium, copper, tellurium, arsenic, lead, bismuth, and precious metals gold and silver in the copper anode slime are recovered. The method adopts two-step vacuum carbothermal reduction to replace reduction smelting of anode slime and stepwise blowing of noble lead in the traditional pyrometallurgy, and avoids the emission of arsenic-containing soot in the traditional process. The recovered gold-rich residue contains almost no base metals such as lead, bismuth, antimony, and arsenic. After subjecting the gold-rich residue to leaching gold by chlorination and reduction, a gold powder could be obtained therefrom with a lower content of base metals than traditional processes. Therefore, the method greatly reduces the amount of produced slag, shortens the production cycle, and reduces the loss of precious metals in the slag.

Abstract: An apparatus and method for preparing high-purity spherical magnesium and/or high-purity magnesium powder are provided. The apparatus includes a vertical furnace body, a heating zone, and a condensing zone, where a periphery of the condensing zone is provided with a first thermal insulation device and a second thermal insulation device sequentially from bottom to top, and each of the first thermal insulation device and the second thermal insulation device is removably arranged; the periphery of the condensing zone is further provided with a liquid cooling device; a gas inlet and a gas outlet are formed in the condensing zone; and an inner wall of the condensing zone is provided with an arrangement structure configured to arrange a collection device. A heating temperature of a material and condensation conditions in the condensing zone are controlled to make an evaporated magnesium vapor condensed on the collection device in the condensing zone.

Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.

Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.

Abstract: A method for comprehensively processing noble lead provided and utilizes two instances of vacuum distillation to realize an open circuit of arsenic, lead, antimony and bismuth and the high-efficiency enrichment of precious metals of gold and silver, and can obtain elemental arsenic, a lead-bismuth-antimony alloy, a silver alloy and a copper alloy, respectively. The lead-bismuth-antimony alloy, the silver alloy and the copper alloy are processed by oxidation refining, electrorefining and chlorination refining to obtain refined lead, refined antimony, antimony trioxide, electrolytic silver and electrolytic copper, and to realize gold enrichment. The entire process has advantages of high metal direct yield, low energy consumption, short flow chart, simple equipment, etc., and vacuum distillation belongs to a physical process in which the alloy can be separated only by means of the difference in saturated vapor pressure between the metals, without generation of wastewater, waste gas and waste residue.

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).